Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

被引:174
作者
Gordon, AN
Finkler, N
Edwards, RP
Garcia, AA
Crozier, M
Irwin, DH
Barrett, E
机构
[1] Walt Disney Mem Canc Inst, Orlando, FL USA
[2] Sammons Canc Ctr, Dallas, TX USA
[3] Magee Womens Hosp, Pittsburgh, PA USA
[4] USC, Norris Canc Hosp, Los Angeles, CA USA
[5] Texas Oncol Canc Ctr, Austin, TX USA
[6] Alta Bates Comprehens Canc Ctr, Berkeley, CA USA
[7] OSI Pharmaceut Inc, Boulder, CO USA
关键词
EGFR inhibition; erlotinib; ovarian cancer; targeted therapies;
D O I
10.1111/j.1525-1438.2005.00137.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this single-arm, phase II study was to estimate the tumor response rate and safety profile of erlotinib HCl (erlotinib, Tarceva (TM), OSI-774) monotherapy in patients with refractory, recurrent, HER1/EGFR-positive epithelial ovarian tumors, who had failed prior taxane and/or platinum-based chemotherapy. Thirty-four patients received 150 mg erlotinib orally once daily for up to 48 weeks or until disease progression or dose-limiting toxicity. Two patients had partial responses, lasting 8+ and 17 weeks, giving an objective response rate of 6% (95% confidence interval [CI], 0.7-19.7%). Fifteen patients (44%) had stable disease, and 17 patients (50%) had progressive disease. Median overall survival was 8 months (95% CI, 5.7-12.7 months), with a 1-year survival rate of 35.3% (95% CI, 19.8-53.5%). Patients with rash survived significantly longer than those without (P= 0.009), correlating with rash grade. Erlotinib was generally well tolerated. The most frequent erlotinib-related adverse events were rash (68%) and diarrhea (38%). Erlotinib had marginal activity but was generally well tolerated. The safety profile appears more favorable than typically experienced with standard chemotherapeutic agents, which is encouraging in these heavily pretreated patients. Combination of erlotinib with chemotherapy or other targeted agents should be considered.
引用
收藏
页码:785 / 792
页数:8
相关论文
共 30 条
[1]  
[Anonymous], 2003, P AM SOC CLIN ONCOLO
[2]  
[Anonymous], 2003, P AM SOC CLIN ONCOL
[3]   Relapsed ovarian cancer: Challenges and management strategies for a chronic disease [J].
Armstrong, DK .
ONCOLOGIST, 2002, 7 :20-28
[4]   The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer [J].
Bartlett, JMS ;
Langdon, SP ;
Simpson, BJB ;
Stewart, M ;
Katsaros, D ;
Sismondi, P ;
Love, S ;
Scott, WN ;
Williams, ARW ;
Lessells, AM ;
Macleod, KG ;
Smyth, JF ;
Miller, WR .
BRITISH JOURNAL OF CANCER, 1996, 73 (03) :301-306
[5]   EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION IN NORMAL OVARIAN EPITHELIUM AND OVARIAN-CANCER .1. CORRELATION OF RECEPTOR EXPRESSION WITH PROGNOSTIC FACTORS IN PATIENTS WITH OVARIAN-CANCER [J].
BERCHUCK, A ;
RODRIGUEZ, GC ;
KAMEL, A ;
DODGE, RK ;
SOPER, JT ;
CLARKEPEARSON, DL ;
BAST, RC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (02) :669-674
[6]  
Brader K. R., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P258
[7]  
DAI Q, 2003, P AM ASSOC CANC RES, V44, P4866
[8]  
DUBOIS A, 1997, SEMIN ONCOL S15, V24, pS44
[9]  
Dunton CJ, 2002, ONCOLOGIST, V7, P11
[10]  
FORD M, 1994, BR J CANC S24, V71, P16